Harbourvest Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Harbourvest Partners’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,533	Closed	-$17.2K	–	34
2024 Q3	$17.2K	Hold	11,533	–	–	0.01%	33
2024 Q2	$18.7K	Hold	11,533	–	–	0.01%	37
2024 Q1	$19.6K	Hold	11,533	–	–	0.01%	46
2023 Q4	$35.8K	Hold	11,533	–	–	0.01%	50
2023 Q3	$70.8K	Hold	11,533	–	–	0.02%	53
2023 Q2	$72.2K	Hold	11,533	–	–	0.02%	55
2023 Q1	$55K	Hold	11,533	–	–	0.02%	60
2022 Q4	$100K	Hold	11,533	–	–	0.03%	59
2022 Q3	$137K	Hold	11,533	–	–	0.04%	60
2022 Q2	$164K	Hold	11,533	–	–	0.05%	56
2022 Q1	$240K	Hold	11,533	–	–	0.05%	60
2021 Q4	$266K	Buy	11,533 +3,841	+50%	+$92.8K	0.03%	56
2021 Q3	$229K	Hold	7,692	–	–	0.02%	51
2021 Q2	$263K	Hold	7,692	–	–	0.03%	45
2021 Q1	$253K	Buy	+7,692	New	+$303K	0.03%	38

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners's PMVP Position: Q4 2024 in Review

Harbourvest Partners sold out of PMV Pharmaceuticals (PMVP) in Q4 2024, closing a stake of 11,533 shares — an estimated $17.2K sold.

Harbourvest Partners first reported a position in PMVP in Q1 2021 and held it in 15 quarters. The position peaked at $266K in Q4 2021. 70 funds tracked by Wall St. Rank hold PMVP as of Q4 2024.

Harbourvest Partners reported no remaining PMV Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Harbourvest Partners sold 11,533 PMV Pharmaceuticals shares in Q4 2024, an estimated $17.2K.
Harbourvest Partners first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 15 quarters.
Harbourvest Partners's PMV Pharmaceuticals position peaked at $266K in Q4 2021.
70 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2024.

Based on Harbourvest Partners's 13F filing for Q4 2024, filed 14 Feb 2025.